Literature DB >> 3017392

The effect of moderate urine alkalinisation on low dose diethylcarbamazine therapy in patients with onchocerciasis.

K Awadzi, K K Adjepon-Yamoah, G Edwards, M L Orme, A M Breckenridge, H M Gilles.   

Abstract

Twenty-one patients with moderate to heavy infections with O. volvulus were treated with 25 mg of diethylcarbamazine (DEC) citrate twice daily for 10 days. In 11 patients the urine was made alkaline with sodium bicarbonate, 2 g, administered 6 hourly for three doses daily beginning 1 day before DEC was started and continued throughout the DEC therapy. Ten patients served as controls. The mean pre-dose plasma DEC concentration during treatment and the mean plasma DEC half-life were significantly higher in bicarbonate treated patients as compared to controls. Total urinary excretion of DEC was significantly less in the bicarbonate treated group than in controls. Mean overall total reaction was higher in bicarbonate-treated patients but the difference was not significant. The bicarbonate-treated group achieved a significantly greater reduction in skin microfilarial counts than the control group as assessed 1 week after completion of therapy, but there was little difference at 1 month. Microfilarial killing was associated with microfilarial mobilisation, alteration in peripheral leucocytes and elevation in serum aminotransferases in both groups. There was no effect of DEC on the number of adult worms recovered in nodules removed at the end of the therapy. This study indicates that moderate urinary alkalinisation alters the kinetics of DEC and the therapeutic response. However the severity of clinical reaction coupled with the inadequate level of microfilarial killing achieved make it unlikely that manipulation of urinary pH will be of practical value in onchocerciasis chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3017392      PMCID: PMC1400978          DOI: 10.1111/j.1365-2125.1986.tb05232.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  [Onchocerciasis chemotherapy (author's transl)].

Authors:  J Prod'hon; J P Moreau; C Mongin
Journal:  Med Trop (Mars)       Date:  1979 Nov-Dec

2.  The chemotherapy of onchocerciasis VII. The effect of prednisone on the Mazzotti reaction.

Authors:  K Awadzi; M L Orme; A M Breckenridge; H M Gilles
Journal:  Ann Trop Med Parasitol       Date:  1982-06

3.  The chemotherapy of onchocerciasis IX. The effect of prednisone plus cyproheptadine on the Mazzotti reaction.

Authors:  K Awadzi; M L Orme; A M Breckenridge; H M Gilles
Journal:  Ann Trop Med Parasitol       Date:  1982-10

4.  The Mazzotti reaction following treatment of onchocerciasis with diethylcarbamazine: clinical severity as a function of infection intensity.

Authors:  H Francis; K Awadzi; E A Ottesen
Journal:  Am J Trop Med Hyg       Date:  1985-05       Impact factor: 2.345

5.  The chemotherapy of onchocerciasis X. An assessment of four single dose treatment regimes of MK-933 (ivermectin) in human onchocerciasis.

Authors:  K Awadzi; K Y Dadzie; H Shulz-Key; D R Haddock; H M Gilles; M A Aziz
Journal:  Ann Trop Med Parasitol       Date:  1985-02

6.  Effects of various concentrations of diethylcarbamazine citrate applied as eye drops in ocular onchocerciasis, and the possibilities of improved therapy from continuous non-pulsed delivery.

Authors:  B R Jones; J Anderson; H Fuglsang
Journal:  Br J Ophthalmol       Date:  1978-07       Impact factor: 4.638

7.  Chemotherapy of onchocerciasis: a controlled clinical trial of topical diethylcarbamazine (DEC) in Guatemala.

Authors:  H R Taylor; M E Langham; E M de Stahl; L N Figueroa; F Beltranena
Journal:  Tropenmed Parasitol       Date:  1980-09

8.  Diethylcarbamazine disposition in patients with onchocerciasis.

Authors:  G Edwards; K Awadzi; A M Breckenridge; H M Gilles; M L Orme; S A Ward
Journal:  Clin Pharmacol Ther       Date:  1981-10       Impact factor: 6.875

9.  The effect of variations in urinary pH on the pharmacokinetics of diethylcarbamazine.

Authors:  G Edwards; A M Breckenridge; K K Adjepon-Yamoah; M L Orme; S A Ward
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

10.  Ocular changes with oral and transepidermal diethylcarbamazine therapy of onchocerciasis.

Authors:  H R Taylor; B M Greene
Journal:  Br J Ophthalmol       Date:  1981-07       Impact factor: 4.638

View more
  6 in total

Review 1.  Diethylcarbamazine in the treatment of patients with onchocerciasis.

Authors:  K Awadzi; H M Gilles
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of anthelmintic drugs.

Authors:  G Edwards; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

3.  Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer.

Authors:  M G Wientjes; R A Badalament; J L Au
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 4.  Pharmacokinetic and pharmacodynamic issues in the treatment of parasitic infections.

Authors:  G Edwards; S Krishna
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-17       Impact factor: 3.267

Review 5.  Clinical pharmacokinetics in the treatment of tropical diseases. Some applications and limitations.

Authors:  G Edwards; P A Winstanley; S A Ward
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

6.  Epidemiological screening and xenomonitoring for human lymphatic filariasis infection in select districts in the states of Maharashtra and Karnataka, India.

Authors:  Vishal Khatri; Nitin Amdare; Nikhil Chauhan; Namdev Togre; Maryada V Reddy; Subhash L Hoti; Ramaswamy Kalyanasundaram
Journal:  Parasitol Res       Date:  2019-01-21       Impact factor: 2.289

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.